Abstract: Equid alphaherpesviruses 1 (EHV-1) and 4 (EHV-4) are closely related and both endemic in horses worldwide. Both viruses replicate in the upper respiratory tract, but EHV-1 may additionally lead to abortion and equine herpesvirus myeloencephalopathy (EHM). We focused on antibody responses in horses against the receptor-binding glycoprotein D of EHV-1 (gD1), which shares a 77% amino acid identity with its counterpart in EHV-4 (gD4). Both antigens give rise to cross-reacting antibodies, including neutralizing antibodies. However, immunity against EHV-4 is not considered protective against EHM. While a diagnostic ELISA to discriminate between EHV-1 and EHV-4 infections is available based on type-specific fragments of glycoprotein G (gG1 and gG4, respectively), the type-specific antibody reaction against gD1 has not yet been sufficiently addressed. Starting from the N-terminus of gD1, we developed luciferase immunoprecipitation system (LIPS) assays, using gD1-fragments of increasing size as antigens, i.e. gD1_83 (comprising the first 83 amino acids), gD1_160, gD1_180, and gD1_402 (the full-length molecule). These assays were then used to analyse panels of horse sera from Switzerland (n = 60) and Iceland (n = 50), the latter of which is considered EHV-1 free. We detected only one true negative horse serum from Iceland, whereas all other sera in both panels were seropositive for both gG4 (ELISA) and gD1 (LIPS against gD1_402). In contrast, seropositivity against gG1 was rather rare (35% Swiss sera; 14% Icelandic sera). Therefore, a high percentage of antibodies against gD1 could be attributed to cross-reaction and due to EHV-4 infections. In contrast, the gD1_83 fragment was able to identify sera with type-specific antibodies against gD1. Interestingly, those sera stemmed almost exclusively from vaccinated horses. Although it is uncertain that the N-terminal epitopes of gD1 addressed in this communication are linked to better protection, we suggest that in future vaccine developments, type-common antigens should be avoided, while a broad range of type-specific antigens should be favored.
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
The research article focuses on the antibody responses in horses against a specific protein present in Equid alphaherpesviruses-1 (EHV-1). The study uses luciferase immunoprecipitation system (LIPS) assays and also discusses implications of the findings on potential vaccine developments.
Understanding the Research Background
Equid alphaherpesviruses 1 (EHV-1) and 4 (EHV-4) are closely related viruses, which cause infections in horses globally. Both these viruses primarily replicate in the upper respiratory tract. However, EHV-1 also results sometimes in abortion and equine herpesvirus myeloencephalopathy (EHM).
The study examines the antibody responses elicited in horses against the glycoprotein D of EHV-1 (gD1), which is a protein involved in virus entry into cells.
The gD1 protein shares 77% of its amino acid sequence similarity with the equivalent protein found in EHV-4 (gD4). As a result, it is common for both proteins to instigate the production of cross-reacting antibodies, including neutralizing antibodies that can inhibit a virus’s ability to infect cells.
Despite an existing immunity against EHV-4, it does not offer protection against the more severe symptoms of EHV-1 infections like EHM.
The Research Methodology and Findings
The researchers developed luciferase immunoprecipitation system (LIPS) assays, in which different sizes of the gD1 protein were used as antigens, to understand the antibody reactions against gD1 protein in horses.
The LIPS assays were tested on blood serum samples from horses in Switzerland (60 samples) and Iceland (50 samples). Iceland is considered free of EHV-1.
All the serum samples, barring one from Iceland, were found to have antibodies against both gD1 and gG4 (another protein in EHV-4), detected through the LIPS and ELISA methods respectively, indicating most horses were previously exposed to an infection with EHV-4.
However, only 35% of Swiss samples and 14% of Icelandic samples had antibodies against gG1, implying a high percentage of antibodies against gD1 are likely due to cross-reaction resulting from EHV-4 infections.
Interestingly, a smaller fragment of the gD1 protein (gD1_83) was found to be successful in recognizing type-specific antibodies against gD1, and these were mostly found in vaccinated horses.
Implications and Recommendations
While the study does not conclusively establish that the presence of antibodies against specific areas (epitopes) of gD1 provides better protection, it suggests that future vaccine developments should focus on type-specific antigens.
Researchers recommend avoiding type-common antigens that could lead to cross-reactivity and lack of specific immunity against EHV-1 or EHV-4 infections.
Cite This Article
APA
Schramm A, Ackermann M, Eichwald C, Aguilar C, Fraefel C, Lechmann J.
(2024).
Antibody reactions of horses against various domains of the EHV-1 receptor-binding protein gD1.
PLoS One, 19(7), e0301987.
https://doi.org/10.1371/journal.pone.0301987
Thórhallsdóttir K, Svansson V, Larsen LE. Investigations of equine alphaherpesvirus type 1 and 4 infections in a group of foals and their dams in Iceland. Technical University of Denmark 2013.
Ma G, Azab W, Osterrieder N. Equine herpesviruses type 1 (EHV-1) and 4 (EHV-4) —Masters of co-evolution and a constant threat to equids and beyond. Vet Microbiol 2013;167: 123–134.
Osterrieder N, Van de Walle GR. Pathogenic potential of equine alphaherpesviruses: The importance of the mononuclear cell compartment in disease outcome. Vet Microbiol 2010;143: 21–28.
Azab W, Osterrieder N. Glycoproteins D of Equine Herpesvirus Type 1 (EHV-1) and EHV-4 Determine Cellular Tropism Independently of Integrins. J Virol 2012;86: 2031–2044.
Holz CL, Nelli RK, Eilidh Wilson M, Zarski LM, Azab W, Baumgardner R. Viral genes and cellular markers associated with neurological complications during herpesvirus infections. Journal of General Virology 2017;98: 1439–1454.
Burbelo PD, Goldman R, Mattson TL. A simplified immunoprecipitation method for quantitatively measuring antibody responses in clinical sera samples by using mammalian-produced Renilla luciferase-antigen fusion proteins. BMC Biotechnol 2005;5.
Burbelo PD, Lebovitz EE, Notkins AL. Luciferase immunoprecipitation systems for measuring antibodies in autoimmune and infectious diseases. Translational Research 2015.
Li J, Wang G, Yang D, Zhao B, Zhao Y, Liu Y. Development of luciferase-linked antibody capture assay based on luciferase immunoprecipitation systems for antibody detection of porcine reproductive and respiratory syndrome virus. BMC Biotechnol 2018;18.
Hardmeier I, Schoster A. Association of EHV-1 antibody concentrations with shedding of EHV-1 in healthy horses and horses with EHV-1 infections. University of Zürich 2018. Aug.
Crabb BS, Studdert MJ. Epitopes of Glycoprotein G of Equine Herpesviruses 4 and 1 Located near the C Termini Elicit Type-Specific Antibody Responses in the Natural Host. J Virol 1993.
Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O. Highly accurate protein structure prediction with AlphaFold. Nature 2021;596: 583–589.
Mirdita M, Schütze K, Moriwaki Y, Heo L, Ovchinnikov S, Steinegger M. ColabFold: making protein folding accessible to all. Nat Methods 2022;19: 679–682.
Vetter J, Papa G, Seyffert M, Gunasekera K, De Lorenzo G, Wiesendanger M. Rotavirus Spike Protein VP4 Mediates Viroplasm Assembly by Association to Actin Filaments. J Virol 2022;96.
Damerval C, De Vienne D, Zivy M, Thiellement H. Technical improvements in two-dimensional electrophoresis increase the level of genetic variation detected in wheat-seedling proteins. Electrophoresis 1986;7: 52–54.
Wellington JE, Gooley AA, Love DN, Whalley JM. N-terminal sequence analysis of equine herpesvirus 1 glycoproteins D and B and evidence for internal cleavage of the gene 71 product. Journal of General Virology 1996;77: 75–82.
Allkofer A GM, RE LR, RM LG, WC VM, CA. Primary vaccination in foals: a comparison of the serological response to equine influenza and equine herpesvirus vaccines administered concurrently or 2 weeks apart. Arch Virol 2021;166: 571–579.